Table 2 Onset age and correlation with AML of reviewed myeloid sarcoma patients
MS site | Onset Age (year) | Without AML | Preceding AML | Coinciding with AML | AML Relapse |
|---|---|---|---|---|---|
Vulva | 25–78 (49.5 ± 9.3) | 1 (16.7%) | 1 (16.7%) | 4 (66.7%) | ─ |
Vagina | 55–61 (58 ± 3) | 1 (100%) | ─ | ─ | ─ |
Uterine cervix | 23–63 (41.3 ± 2.2) | 10 (58.8%) | 4 (23.5%) | 2 (11.8%) | 1 (5.9%) |
Uterine body | 33–44 (38.3 ± 3.2) | 3 (100%) | ─ | ─ | ─ |
Ovary | 22–36 (27.5 ± 1.4) | 8 (66.7%) | 1 (8.3%) | 1 (8.3%) | 2 (16.7%) |
Multifocal | 25–51 (40.1 ± 2.8) | 5 (62.5%) | 1 (12.5%) | ─ | 2 (25%) |
Total | 22–78 (39.2 ± 1.7) | 28 (59.6%) | 7 (14.9%) | 7 (14.9%) | 5 (10.6%) |